Andexanet alfa for acute major bleeding associated with factor xa inhibitors

New England Journal of Medicine

Volumn 375, Issue 12, 2016, Pages 1131-1141

  Connolly, Stuart J ^a   Milling, Truman J ^b,w   Eikelboom, John W ^a   Michael Gibson, C ^c   Curnutte, John T ^d   Gold, Alex ^d   Bronson, Michele D ^d   Lu, Genmin ^d   Conley, Pamela B ^d   Verhamme, Peter ^e   Schmidt, Jeannot ^f   Middeldorp, Saskia ^h   Cohen, Alexander T ⁱ   Beyer Westendorf, Jan ^j   Albaladejo, Pierre ^g   Lopez Sendon, Jose ^k   Goodman, Shelly ^d   Leeds, Janet ^d   Wiens, Brian L ^d   Siegal, Deborah M ^a   Zotova, Elena ^a   Meeks, Brandi ^a   Nakamya, Juliet ^a   Ting Lim, W ^a   Crowther, Mark ^a   Anand, R ^l   Bastani, A ^m   Caterino, J ⁿ   Clark, C ^m   Concha, M ^o   Cornell, J ^p   Eriksson, E ^q   Fermann, G ^r   Fulmer, J ^s   Goldstein, J ^t   Kereiakes, D ^u   Lotfipour, S ^v   Moll, S ^x   Pallin, D ^y   Patel, N ^z   Refaai, M ^aa   Rehman, M ^ab   Schmaier, A ^ac   Schwarz, E ^ad   Shillinglaw, W ^ae   Sinert, R ^af   Singer, A ^ag   Smith, L ^ah   Takata, T ^ai   Venkat, A ^aj   Weinstein, D ^ak   Welker, J ^al   Welsby, I ^am   Wiener, S ^an   Wilson, J ^ao   Blostein, M ^ap   Van Keer, L ^aq   Verschuren, F ^ar   Coppens, M ^h   van Wissen, S ^as   Alikhan, R ^at   Breen, K ⁱ   Hall, R ^au   more..

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Portola Pharmaceuticals   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g UNIV GRENOBLE ALPES   (France)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l HOLY CROSS HOSPITAL   (United States)

^m WILLIAM BEAUMONT HOSPITAL   (United States)

ⁿ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^o SARASOTA MEMORIAL HOSPITAL   (United States)

^p MARSHALL UNIVERSITY   (United States)

^q MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^r UNIVERSITY OF CINCINNATI   (United States)

^s River City Clinical Research   (United States)

^t MASSACHUSETTS GENERAL HOSPITAL   (United States)

^u The Carl & Edyth Lindner Center for Research & Education   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w University Medical Center Brackenridge   (United States)

^x UNIVERSITY OF NORTH CAROLINA   (United States)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^aa UNIVERSITY OF ROCHESTER   (United States)

^ab HENRY FORD HOSPITAL   (United States)

^ac UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^ad WASHINGTON UNIVERSITY   (United States)

^ae Mission Hospital   (United States)

^af NEW YORK CITY HEALTH AND HOSPITALS CORPORATION   (United States)

^ag STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^ah WAKE FOREST BAPTIST HEALTH   (United States)

^ai Texas Health Research and Education Institute   (United States)

^aj ALLEGHENY SINGER RESEARCH INSTITUTE   (United States)

^ak Atlantic Clinical Research Collaborative Cardiology   (United States)

^al ANNE ARUNDEL MEDICAL CENTER   (United States)

^am DUKE UNIVERSITY   (United States)

^an SUNY DOWNSTATE MEDICAL CENTER   (United States)

^ao TAMPA GENERAL HOSPITAL   (United States)

^ap MCGILL UNIVERSITY   (Canada)

^aq DEPARTMENT OF CARDIOLOGY   (Belgium)

^ar CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^as ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^at UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^au UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; RIVAROXABAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE DISEASE; ACUTE MAJOR BLEEDING; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EMERGENCY WARD; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMOSTASIS; HUMAN; INFUSION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOSIS; TIME TO TREATMENT; TREATMENT DURATION; VERY ELDERLY; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; INTRACRANIAL HEMORRHAGES; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PROSPECTIVE STUDY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; ENOXAPARIN; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; MALE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; RECOMBINANT PROTEINS; RIVAROXABAN; THROMBOSIS;

EID: 84988893659     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1607887     Document Type: Article

References (11)

1. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
4. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
5. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-51.
6. Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol 2016; 9: 115-22.
7. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-24.
8. Colman RW, Clowes AW, George JN, et al. Overview of hemostasis. In: Colman RW, Clowes AW, George JN, et al., eds. Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2006: 1-16.
9. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on Vitamin K antagonists presenting with major bleeding: A randomized, plasmacontrolled, phase IIIb study. Circulation 2013; 128: 1234-43.
10. Hahn GJ, Meeker WQ. Statistical intervals: A guide for practitioners. New York: John Wiley, 1991.
11. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-20